Everads Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 3

Everads General Information

Description

Developer of retinal treatment therapy and technology designed to overcome significant technical challenges in effective suprachoroidal injection. The company's technology offers drug delivery and distribution, and offers potential long-term therapeutic effects, enabling patients to get improved compliance and outcomes.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 27 Habarzel Street, Migdalei Orr
  • Building A 5th Floor
  • Tel Aviv 6971039
  • Israel
Primary Industry
Drug Delivery
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • 27 Habarzel Street, Migdalei Orr
  • Building A 5th Floor
  • Tel Aviv 6971039
  • Israel

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Everads Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Accelerator/Incubator Completed Clinical Trials - Phase 1
2. Grant 29-Feb-2020 Completed Clinical Trials - Phase 1
1. Seed Round 01-Jan-2017 $950K $950K Completed Clinical Trials - Phase 1
To view Everads’s complete valuation and funding history, request access »

Everads Patents

Everads Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026053205-A1 Means and method for suprachoroidal drug delivery to a back of an eye Pending 05-Sep-2024
US-20240423832-A1 Surgical fixation tool with coupling to injector/syringe Pending 31-Aug-2021
WO-2023031723-A1 Surgical fixation tool with coupling to injector/syringe Inactive 31-Aug-2021
EP-4210644-A1 Surgical fixation tool Active 08-Sep-2020
EP-4210644-B1 Surgical fixation tool Active 08-Sep-2020 A61F9/007
To view Everads’s complete patent history, request access »

Everads Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Everads Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Horizon 2020 Government
RAD BioMed Impact Investing Minority
ARC Innovation Center Accelerator/Incubator
To view Everads’s complete investors history, request access »

Everads Investments (1)

Everads’s most recent deal was a Joint Venture with Therapies for Retinal Diseases (Everads / VivaVision Biopharma). The deal was made on 06-Jan-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Therapies for Retinal Diseases (Everads / VivaVision Biopharma) 06-Jan-2023 Joint Venture Drug Discovery
To view Everads’s complete investments history, request access »

Everads FAQs

  • When was Everads founded?

    Everads was founded in 2017.

  • Where is Everads headquartered?

    Everads is headquartered in Tel Aviv, Israel.

  • What is the size of Everads?

    Everads has 9 total employees.

  • What industry is Everads in?

    Everads’s primary industry is Drug Delivery.

  • Is Everads a private or public company?

    Everads is a Private company.

  • What is Everads’s current revenue?

    The current revenue for Everads is .

  • How much funding has Everads raised over time?

    Everads has raised $950K.

  • Who are Everads’s investors?

    Horizon 2020, RAD BioMed, and ARC Innovation Center have invested in Everads.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process